Interim report January – September 2026: Increasing profitability and important strategic progress

Third quarter 2026 (July – September)

  • Net sales amounted to SEK 260.2 (263.6) million, a decrease of 1 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales also decreased by 1 percent.
  • License revenue amounted to SEK 76.0 (65.5) million and accounted for 29 (25) percent of net sales.
  • The gross margin was 68 (65) percent.
  • Operating profit amounted to SEK 32.0 (27.2) million.
  • Net profit amounted to SEK 34.1 (20.4) million, corresponding to earnings per share of SEK 0.67 (0.40).
  • Cash flow from operating activities amounted to SEK 42.5 (-4.4) million. As at September 30, 2026, cash and cash equivalents amounted to SEK 674.9 (597.4) million.

First nine months of 2026 (January – September)

  • Net sales amounted to SEK 750.2 (723.5) million, an increase of 4 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 5 percent.
  • License revenue amounted to SEK 228.4 (208.3) million and accounted for 30 (29) percent of net sales.
  • The gross margin was 68 (66) percent.
  • Operating profit amounted to SEK 87.5 (28.7) million.
  • Net profit amounted to SEK 73.6 (33.6) million, corresponding to earnings per share of SEK 1.44 (0.66).
  • Cash flow from operating activities amounted to SEK 123.1 (6.9) million.

Gothenburg, Sweden, November 12, 2026
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
https://surgicalscience.com/aktien/financial-report

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

Tom Englund, CEO
Telephone: +46-70-916 16 81
E-mail: tom.englund@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

Surgical Science is a global leader in evidence-based medical simulation. The company’s virtual reality simulators and customized training solutions enable surgeons and healthcare professionals to practice and improve their skills outside the operating room – enhancing patient safety and clinical outcomes. Also, Surgical Science partners with medical technology and robotics companies to integrate tailor-made simulation technology into their devices, helping them accelerate innovation and gain a competitive edge.

Surgical Science has approximately 320 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Cleveland, US; Cardiff, UK; and Hong Kong and Shenzhen, China. Through sales offices in these markets and a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market, Stockholm, Sweden. Certified Adviser is DNB Carnegie Investment Bank AB.

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-12 07:30 CET.

Attachments

261112 Q32026 ENG

261112 Q32026 ENG